Please assess the completion status of the following clinical trial:

Trial Title: Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed written informed consent~2. Women ≥18 years of age~3. Histologically- or cytologically-confirmed breast cancer for whom IV paclitaxel (as Taxol or generic) monotherapy has been recommended by their oncologist~4. Measurable metastatic target lesion disease measurable by CT scan as per RECIST v1.1 criteria~5. Adequate hematological status as demonstrated by not requiring granulocyte-colony stimulating factor (G-CSF) or transfusion support to achieve the following at Screening:~   * Absolute neutrophil count (ANC) ≥1.5 x 109/L~  * Platelet count ≥100 x 109/L~  * Hemoglobin ≥10 g/dL~6. Adequate liver function as demonstrated by:~   * Total bilirubin within normal limits (WNL)~  * Alanine aminotransferase and aspartate aminotransferase ≤3 x upper limit of normal (ULN)~  * Alkaline phosphatase ≤3 x ULN or ≤5 x ULN if bone metastasis is present~  * Gamma glutamyl transferase (GGT) ≤5 x ULN~7. Adequate renal function as demonstrated by serum creatinine ≤1.5 x ULN~8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~9. Life expectancy of at least 6 months, in the judgement of the investigator~10. Subjects must be postmenopausal (≥12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception and agree to used of contraception for 30 days after their last dose of assigned study treatment.~11. Subjects who are of childbearing potential must have a negative screening serum pregnancy test.~Exclusion Criteria:~1. Have not recovered to ≤ Grade 1 toxicity from previous anticancer treatments or previous investigational products~2. If previously treated with a taxane (paclitaxel or docetaxel) as part of anthracycline-based adjuvant chemotherapy or for metastatic disease, the subject relapsed less than 1 year following treatment~3. Only evidence of metastatic disease is to bone or other nontarget or nonmeasurable lesions (including, for example, ascites or plural effusion) according to RECIST v1.1 criteria~4. Central nervous system metastasis, including leptomeningeal involvement~5. Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer~6. Are currently receiving other medications intended for the treatment of their malignancy~7. Received radiation therapy within 2 weeks prior to signing informed consent and those for whom radiation therapy is planned within 6 months from the time of signing informed consent~8. Women who are pregnant or breastfeeding~9. Taking a medication known to be a strong P-gp inhibitor or inducer within 14 days of starting treatment~10. Taking an oral medication with a narrow therapeutic index known to be a P-gp substrate within 24 hours prior to start of treatment~11. Taking a medication known to be a strong cytochrome P450 (CYP) 3A4 inhibitor (eg, ketoconazole) or inducer (eg, rifampin or St. John's Wort) within 14 days of starting treatment~12. Taking a medication known to be a strong inhibitor (eg, gemfibrozil) or inducer (eg, rifampin) of CYP2C8 within 14 days of starting treatment~13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements~14. Major surgery to the upper GI tract, or have a history of GI disease or other medical condition that, in the opinion of the Investigator may interfere with oral drug absorption~15. History of significant hypersensitivity-type reactions to paclitaxel or Cremophor EL (polyoxyl 35 castor oil, NF) that would contraindicate the use of IV paclitaxel formulated with Cremophor EL~16. Known allergic reaction or intolerance to contrast media~17. Documented history of true systemic allergic reaction to 3 or more medications~18. For whom the Investigator believes that participation in this study would not be acceptable~19. Known chronic hepatitis or cirrhosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oraxol (paclitaxel + HM30181AK-US) (Type: EXPERIMENTAL): Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets
- IV paclitaxel (Type: ACTIVE_COMPARATOR): IV paclitaxel - supplied as Taxol or generic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete